This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Aug 8, 2024
•
9 min read
Novo Nordisk posts disappointing Q2 earnings, Chugai acquires Japan rights to Roche IBD med, Amgen's Horizon acquisition continues to pay off in Q2 earnings, IDRx's $120M Series B, Pharmacosmos buys G1 Therapeutics, Novo pulls back Wegovy heart failure submission, and insider trading doesn't pay
Aug 7, 2024
11 min read
Agios to collect a fat $1.1B milestone payment after FDA approval, Symbiotic Capital life science credit firm launches with $600M, Shinobi Therapeutics extends Series A + lands $59M grant, Pfizer invests in antimicrobial resistance, Merck & Co. signs T-cell engager bispecific partnership with Daiichi Sankyo, Bayer touts massive management cuts over H1 2024, BioMarin shrinks Roctavian gene therapy ambitions
Aug 6, 2024
6 min read
Bayer posts heart failure Ph3 win, Mallinckrodt sells Therakos division to PE firm at a substantial loss, MBX Biosciences $63.5M Series C, Actinium turns to partnership after FDA rejection, BioNTech posts $883M net loss for Q2, and gene therapy biotech Lacerta Therapeutics shuts down
Aug 5, 2024
Vir in-licences three Sanofi T-cell engager clinical assets, Paragon Therapeutic's fourth opco launches with $80M, Vertex boosts 2024 outlook on Casgevy sales (and also cuts two rare disease Ph1 assets), Eli Lilly's Zepbound, Mounjaro no longer on US shortage list, Ribon Therapeutics shutters
Aug 2, 2024
10 min read
Gene therapy legend James Wilson launches two new companies, Adaptimmune's engineered cell therapy for solid tumors gets historic accelerated approval, venBio closes fifth life science fun at $500M+, Sanofi commits $1.4B for new insulin manufacturing facility, uniQure decimates its workforce via 65% layoffs, and Novartis continues to fight FDA's Entresto generic approval
Aug 1, 2024
J&J lands FDA approval for "foundational" multiple myeloma combo, Eisai drops more Leqembi data in support of long term use, Umoja cleared to dose first patients with their in situ CAR-T, AIRNA raises $60M Series A, Sanofi sues Sarepta over their DMD gene therapy, and EuroAPI is having a tough "transition year"
Jul 31, 2024
8 min read
BioNTech & Regeneron's mRNA cancer combo reports positive Ph2 data, Merck & Co. takes earnings hit after surprise Gardasil sales slowdown in China, Roche kicks off injectable GLP-1 Ph2 trial, Pfizer looks back on track with recent earnings report, and GLP-1s may help combat smoking
Jul 30, 2024
7 min read
GSK and Flagship sign 10 drug development partnership, Boehringer Ingelheim pays up to $1.3B for Nerio Therapeutics, Merck gets positive Keytruda opinion from CHMP, Spear Bio spears $45M Series A, Cognition Therapeutics handed Ph2 Alzheimer's L, and Pfizer lays off 200+ employees across two sites
Jul 29, 2024
BMS' strong earnings bump stock up 10%, Dexcom stock drops 40% after lowering 2024 sales forecast, multiple big pharmas land EU adcomm thumbs up, while Biogen, Eisai's Leqembi for Alzheimer's gets a thumbs down from the same committee, and Confo Therapeutics raises $65M for small molecule & antibody drug discovery
Jul 26, 2024
Pfizer lands EU approval for their hemophilia B gene therapy, a bunch of big pharmas report earnings, Chevron Doctrine might be resurrected, Ipsen buys pediatric cancer ex-US rights from Day One Biopharmaceuticals, while Roche, AbbVie, and Sanofi all clear out some of their clinical assets
Jul 25, 2024
Pfizer's hemophilia A gene therapy posts positive Ph3, Novo Nordisk's Wegovy gets MHRA approval for a new indication, Gilead unveils full dataset for 100% efficacy HIV prevention shot, highway to funding with Autobahn's $100M Series C, FDA expresses doubt about AstraZeneca's lung cancer med prior to adcomm, and Novo Nordisk has their fourth fire of the year
Jul 24, 2024
Pfizer and Beigene open new facilities, Novo Nordisk buys 200 acres of land, Third Arc launches with $165M, Merck & Co. claim infant RSV win (but no data yet), and sinking generic prices might be exacerbating US drug shortages
